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In the United States, cancer is the second leading cause of death and a major public 
health problem worldwide. This has influenced researchers in the field of nuclear medicine to 
develop new and innovative ways for detecting and treating various forms of cancer. Targeted 
alpha therapy (TAT) is a promising technique for treating metastatic cancer and involves 
delivering a radionuclide to the cancerous cells in the body, where it decays by releasing high-
energy (5-8 MeV) α-particles with high linear energy transfer (LET) over a short (50-100 µm) 
range and relatively low toxicity to the rest of the body. Actinium-225 is an ideal radioisotope 
for TAT due to its short half-life (t1/2=9.92 days) and 3 α-emitting decay daughters. Currently, 
there is not enough 225Ac available to meet expected demand. Therefore, the goal of this research 
is to produce more of the parent radioisotope, thorium-229 (t1/2=7932 years.) The two methods of 
production we chose to investigate are 1) the irradiation of a 226Ra target in the High Flux 
Isotope Reactor (HFIR) at Oak Ridge National Laboratory (ORNL) and 2) the fast neutron 
irradiation of a 230Th target in a particle accelerator.  
This thesis outlines several experiments completed at ORNL to test the feasibility and 
preparation procedures for these two production methods. First, we experimentally evaluated the 
effective neutron cross section of 229Th to be 8.36 ± 0.37 barns, which is more than 3 times lower 
than the current reported value of 30.8 ± 1.5 barns. Second, we tested methods for preparing 
uniformly distributed 230Th targets for fast neutron irradiation at Lawrence Berkeley National 
Laboratory and determined that depositing approximately 25-30 mg of enriched 230Th(NO3)4 
onto a high-purity aluminum substrate and sealing the material with Kapton tape to prevent 
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CHAPTER 1: INTRODUCTION AND BACKGROUND TO 
CANCER THERAPY AND NUCLEAR MEDICINE 
 
 
In the United States, cancer is the second leading cause of death and is a major public 
health problem worldwide [1]. According to the American Cancer Society, cancer is a group of 
diseases characterized by the uncontrolled growth and spread of abnormal cells [2]. If the spread 
of these atypical cells is not controlled, it can result in death. There were projected to be 
1,762,450 new cancer cases and 606,880 cancer deaths in the U.S. alone in 2019 [2].  Current 
clinical treatments for cancer include chemotherapy, radiation therapy, hormone therapy, 
immunotherapy and surgery. Although survival rates have improved from these treatments, each 
technique has its own drawbacks and limitations that can come with severe side effects for the 
patient. Chemotherapy, for example, distributes the toxic chemical therapeutic agents throughout 
the entire body, thus, damaging both cancerous and healthy cells. This limits the amount of dose 
to the cancer cells while causing adverse side effects to the patient including weakness, hair-loss, 
and organ dysfunction [2].  
Radiation therapy is another common type of cancer treatment. There are two main types 
of radiation therapy: external beam and internal [3]. Radiation therapy can kill cancer cells or 




high doses of x-ray radiation to kill cancer cells and reduce the size of tumors. It is a localized 
form of treatment, meaning can only be used to treat a specific tumor or part of the body [3]. 
There is also no way of targeting only the tumor with external beam radiation therapy. As x-rays 
travel through the surface of the skin and body to reach the tumor location, the x-rays also 
deposit their energy and can damage healthy cells in the process due to attenuation [4].  
Internal radiation therapy is a kind of treatment in which a radiation source is placed 
inside the body. The sources can be solid or liquid, and can be removed from the body either by 
a doctor or naturally through excretion of urine and other bodily fluids [3] [5]. Solid source 
internal radiation therapy is called brachytherapy and occurs when seeds, ribbons, or capsules 
containing radioactive sources (usually low energy positron emitters such as 125I and 131Cs) are 
strategically placed directly in or close to the tumor [6].  The radiotherapeutic material is then 
removed either via the same method of implantation or left until fully decayed. Usually dozens 
of treatments are given with this type of therapy and it is often combined with other types such as 
chemotherapy and external beam radiation therapy. Like external beam radiation therapy, solid 
source brachytherapy can only treat localized tumors [3].  
Once cancer has metastasized, or begun spreading to new areas of the body, often by way 
of the lymph system or bloodstream, and is no longer localized to a single tumor area, the cancer 
is classified as advanced [7] [8]. Treatment at this stage is usually given only to slow the growth 
of cancer cells or to relieve symptoms rather than eliminate the cancer [7]. Internal radiation 




The treatment is given by injection or swallowing capsules to get the radioactive drug into the 
bloodstream where it can circulate throughout the body, seeking out and killing cancer cells. The 
most commonly used radioisotope in clinical systemic radiation therapy is the beta-particle 
emitting 131I radioisotope for thyroid cancer, since iodine has a natural affinity for the thyroid 
organ [3] [5]. As technology evolved, scientists in the field of nuclear medicine began to 
research other forms of radiation, such as alpha particles, to destroy cancer cells. The emerging 
technique is known as targeted α-therapy (TAT) and is a promising method for treating 
metastatic cancer due to the unique properties of the charged alpha particle interaction with 
matter [9] [10] [11]. This theory will be described in subsequent sections.   
1.1. What is targeted α-therapy? 
Over the last few decades, interest in the use of alpha-emitting radioisotopes has grown 
immensely [9] [10] [12]. TAT is ideal because the procedure involves delivering a radionuclide 
to the cancerous cells within the body using high-affinity tumor-targeting vehicles such as 
antibodies, peptides, or nanoparticles. The targeting vehicles are necessary for improved drug 
selectivity to target cells through enhanced pharmacodynamics (effect of drug as therapy agent) 
and pharmacokinetics (movement of drug within the body) while also being able to evade 
biological barriers and reach the target sites efficiently [13].  
In targeted alpha therapy, the radionuclide drug decays by releasing high-energy (5-8 
MeV) alpha particles with high-linear energy transfer (50-230 keV/µm) over a short range of 50-
100 µm in tissue and relatively low toxicity to the rest of the body [9] [14] [15] [16]. To break 




particle-emitting radionuclide therapy due to how the particles interact with the body and deposit 
its energy. Linear energy transfer (LET) in dosimetry describes the amount of energy that an 
ionizing particle transfers to the material per unit distance traveled. Compared to beta particles 
that have an LET of 0.1-1 keV/µm, alpha particles have a much higher LET of 50-230 keV/µm 
[17]. Furthermore, the beta particles used in systemic therapy have a relatively long range of 
approximately 2-10 cm in tissue compared to the short 50-100 µm range in tissue for alpha 
particles [18]. This means that alpha particles deposit their energy much more locally than beta 
particles, which promotes higher cytotoxicity (cell toxicity) to the cancer cells and less damage 
to the surrounding healthy tissue than conventional systemic therapy methods.  Targeted alpha 
therapy is a noninvasive, highly potent and localized form of cancer therapy that causes minimal 
damage effects to healthy tissue, proving to be a valuable addition to conventional treatment 
approaches [9] [14] [15] [16] [17] [18]. 
1.2. Actinium for Targeted Alpha Therapy 
Since 223Ra has proven to successfully treat metastatic prostate cancer and became the 
first alpha-emitting radiopharmaceutical approved by the U. S. Food and Drug Administration 
(FDA) in May, 2013 with the drug Xofigo, many other alpha-emitting radionuclides are being 
studied for their potential use in radioimmunotherapy applications [14] [19] [20]. Some clinical 
trials using the radioisotope 213Bi (t1/2 = 45.6 minutes) eluted from a generator has shown 
progress in treating acute myeloid leukemia [9] [21] [22].  
In addition to utilizing 213Bi from a generator, several investigations have undergone 




[23]. The interest in 225Ac for TAT is due to its potency and stems directly from its ability to 
emit four α-particles through its short-lived decay chain (Figure 1: Decay Chain of 225Ac from 233U) 
[9] [16]. The integrated dose from the 225Ac decay chain is approximately 1000x higher than the 
dose from an equivalent quantity of the single α-particle emitting 213Bi [9]. Therefore, much less 
of the initial radiotherapeutic actinium drug would be needed to produce the same effect as using 
213Bi alone.  
 




1.3. Current fundamental understanding of actinium chemistry 
Actinium is the lightest element in the actinide series with a total of 32 known isotopes 
from 205Ac to 236Ac. Only 227Ac and 228Ac are present in nature as part of the 235U and 232Th 
decay chains [16] [24]. As the idea of targeted alpha therapy gained popularity, the interest in 
actinium as a radioisotope for TAT also began to grow; however, the fundamental chemistry of 
the element is not largely well known due its limited supply and high radioactivity of its isotopes 
[16]. 
The chemistry known about the actinium isotope is as follows. Actinium exists most 
stably in the 3+ oxidation state [16] [25]. It has chemical properties that are like those of 
lanthanum 3+. Therefore, lanthanum is a suitable nonradioactive surrogate for experiments 
involving actinium, although it has a smaller ionic radius (1.02 Å for lanthanum compared to 
1.12 Å for actinium) and therefore a higher charge density than its larger counterpart. Because of 
this, actinium is also the most basic 3+ ion with hydrolysis occurring between pH 8.6 and 10.4 
[26]. Higher charge density implies the element more strongly favors the coordination of water 
and subsequent release of a proton at more acidic pH. Due to its lack of polarizability, actinium 
is considered a “hard” Lewis acid according to the Hard and Soft Acids and Bases (HSAB) 
theory, which implies that it bonds most readily with a “hard” nonpolarizable, electronegative 
Lewis base of a similar hardness such as anionic oxygen donors [16].  
Actinium’s lower charge density also relates to a smaller stability constant than that of 
lanthanum. Therefore, it is important to understand that if the lanthanum surrogate is used in 




to perform poorer in experiments under equivalent conditions [27] [28]. This is due to the Ac3+ 
large ionic radius, which results in weaker electrostatic interactions with the ligand atoms.  
To successfully use 225Ac for TAT applications, the radionuclide must be delivered with 
high specificity and remain in or near the targeted cancer cells throughout its decay lifetime.  
This is usually accomplished by covalently linking a tumor-targeting vector to a bifunctional 
chelator (binding agent) that forms a thermodynamically and kinetically stable complex with the 
actinium ion [16]. Unfortunately, the development of these chelators for actinium has been 
hindered due to the poorly understood coordination chemistry of this radioactive ion. Therefore, 
understanding the structural chemistry of Ac3+ is an ongoing area of research and will provide 
useful information about the coordination preferences of the ion, which is important in designing 
these critical chelators. The lack of long-lived actinium radioisotopes (227Ac is the longest-lived 
isotope with a half-life of 22 years) and radiological hazards, however, make the structures 
difficult to characterize [16]. Fried et al. used x-ray powder diffraction to characterize some 
actinium solid state compounds (AcF3, AcCl3, etc.,) which yielded similar values to equivalent 
lanthanum compounds; however, x-ray powder diffraction is not meaningful in determining 
precise coordination geometries about Ac3+ centers, so more research is necessary [16] [29]. 
In addition to our lack of understanding of actinium’s fundamental chemistry, another 
obstacle scientists are currently researching to consider 225Ac for TAT is the alpha recoil effect. 
Having multiple α-emitting daughters in its decay chain is extremely beneficial for increased 
dose to the cancer cells; however, the recoil effect can cause the daughter nuclides to break away 
from the targeting vehicle upon decay, where it could travel and harm other organs and tissues 




fundamental problems [30] [31]. Therefore, 225Ac continues to remain a strong candidate for 




CHAPTER 2: INTRODUCTION TO THE METHODS FOR 
PRODUCING 229TH, PARENT TO 225AC 
 
 
2.1. Current Supply of 225Ac and other methods of production 
One major factor that researchers will face if 225Ac is approved for clinical use is the 
supply of the nuclide. Currently, Oak Ridge National Laboratory (ORNL) is the main provider of 
high-purity 225Ac in the United States, producing approximately 700 mCi per year since 1997 for 
clinical research [9] [14] [32]. The Institute of Physics and Power Engineering in Russia is 
known to produce a similar amount and the Institute for Transuranium Elements (ITU) in 
Germany produces approximately half the amount per year [9] [32]. ORNL recovers the 
actinium as a decay daughter from its 233U stockpile previously produced in the High Flux 
Isotope Reactor (HFIR) [33]. Due to the long half-lives of both the 233U (160,000 years) and 
229Th (7932 years) parents, ORNL is limited on the amount of 225Ac it can generate per year with 
the current stock [9]. The approximately 700 mCi of 225Ac extracted from this stock is estimated 
to be insufficient to meet the estimated 50 Ci demand for the radioisotope if more extensive 
clinical research is completed and the drug gains FDA approval as anticipated [14] [34].  
Therefore, there has been a considerable investment by the scientific community over 
recent years intended to increase the supply to meet current and future 225Ac demands [9] [10] 
[35] [36]. A study was conducted to determine the feasibility of dedicated accelerator production 




of 229Th to be impracticable due to the high beam currents and long irradiation times required [9] 
[37]. Another study was conducted to test the feasibility of producing 225Ra, the parent of 225Ac, 
via the 226Ra[γ,n]225Ra reaction in a linear accelerator, but the conclusions showed that the 
reaction did not yield a viable amount of 225Ra yields for full-scale production application [9] 
[38].  
A recent ongoing effort has created collaboration between Oak Ridge, Brookhaven, and 
Los Alamos National Laboratories under DOE sponsorship to investigate the accelerator 
production of 225Ac by spallation of a natural 232Th metal target via proton bombardment [9] [10] 
[37] [39].  Although this method is promising for large-scale production of 225Ac, the 232Th 
spallation also produces approximately 0.2% by activity at end of bombardment of 227Ac (t1/2 = 
21.77 years,) which contaminates the preferred 225Ac product and decreases the specific activity.  
2.2. Production of 229Th in a Nuclear Reactor 
While there is research currently being conducted to address the 227Ac contamination 
issue, another promising method of 225Ac production has been developed that does not include 
the 227Ac impurity. This method conceptualizes the use of a nuclear reactor to produce the long 
half-lived 229Th from 226Ra (t1/2 = 1600 years) through a series of neutron captures and beta 
decays (Figure 2) [40]. 
 
 





Preliminary experimentation at the High Flux Isotope Reactor (HFIR) at ORNL has 
validated the nuclear reaction pathway and associated cross sections, estimating that >20 mCi of 
229Th per gram of 226Ra can be produced in four to six 25-day irradiation cycles in HIFR [14]. 
Theoretically, 20 mCi of 229Th can produce approximately 120 mCi of 225Ac under ORNL’s 
current processing schedule. Furthermore, most of the 226Ra can be recovered and the process 
repeated for increased production of 229Th, thus, increased production of 225Ac. Another 
advantage for this production method is that the target design and configuration is similar to that 
already used by the lab for 227Ac production, and the procedures to prepare the target, recover, 
and purify the product are already established via ORNL protocol.  
With the current 226Ra target design, however, the sample can only be irradiated for one 
reactor cycle with maximum mass of 600 mg. To maximize 229Th production, the target must be 
irradiated for more than one cycle. Therefore, the HFIR safety basis must be met to gain 
approval for multiple irradiation cycles. Among these research and development tasks are to: 1.) 
evaluate the 229Th fission cross section, 2.) evaluate the Ra/Al cermet thermophysical properties, 
and 3.) perform the heat calculations for multi-cycle irradiation.  
The first of these tasks was carried out at Oak Ridge National Laboratory and will be 
explained in detail later in this thesis. It has been determined that the 229Th that is created during 
irradiation is also the largest contributor of heat in the target. The amount of heat produced in the 
target limits both the irradiation time and the amount of 226Ra that can be included in the target. 
A conservatively high cross section value of 30 barns is used for the current target design heat 




calculations can be determined, which will likely allow for a larger radium target and greater 
amount of 229Th/225Ac produced per irradiation.  
2.3. Production of 229Th Through Fast Neutron Irradiation 
Staff at ORNL also predict that 229Th can be produced via the 230Th(n,2n) 229Th reaction 
by bombarding a thin 230Th target with accelerator-generated fast neutrons. To prove this theory, 
ORNL scientists are collaborating with staff researchers and students from Lawrence Berkeley 
National Laboratory (LBNL,) University of Tennessee – Knoxville (UTK,) and University of 
California – Berkeley. The targets were to be prepared and chemically processed in the 
radiological facility of Building 4501 at ORNL and irradiated with the Thick Target Deuteron 
Breakup Neutron Source (TTDBNS) at the LBNL 88-Inch cyclotron.  
The three specific aims of the collaborative project are to 1.) determine the cross sections 
for the 230Th(n,2n) 229Th reaction for neutron energies 7 < En < 20 MeV, 2.) determine the 
effective production cross sections of 229Th via both proton and deuteron irradiation of 230Th and 
deuteron irradiation of 232Th, and 3.) create a method for producing a uniformly distributed 230Th 
target for charged particle cross section measurements. The work performed and described in 
this thesis was completed in part for the first aim and entails testing preparation methods for the 
230Th target irradiated with accelerator-generated fast neutrons.  
Several experiments were recently performed to determine the 232Th(n,2n)231Th and 
238U(n,2n)237U reaction cross sections [41] [42]. The values measured in these papers are 
approximately 10x higher than those accepted for (p,4n) reaction cross section of a similar target 




[37] [43]. Because of this, a similar trend in results is expected for the 230Th(n,2n)229Th reaction 
cross section, which is currently experimentally unmeasured. Several computational models such 
as TALYS 1.8 and Alice-2017 have been developed to estimate this reaction cross section; 
however, both models carry potentially significant uncertainties because of the absence of fission 
barrier parameters for the 230Th radioisotope [44]. Obtaining a valid experimental cross section 
value for the 230Th(n,2n)229Th reaction will gain new insight on the possibility of using this 
reaction as a viable method to produce 229Th as well as provide a benchmark for modern 
computational nuclear reaction modeling, which will be critical for advanced nuclear reactor 
design, safety, and performance.  
2.4. Underlying Goals and Thesis Objectives 
While 225Ac is a great candidate for the use in targeted alpha therapy for treating metastatic 
cancer, there currently is not enough of the radioisotope to meet expected demand. Therefore, the 
goal of this research is to perform critical steps of the work needed to test two novel methods to 
produce the parent isotope, 229Th. The first production method involves the irradiation of 226Ra in 
the High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory through a series of 
neutron captures. In the second method, scientists plan to test the feasibility of producing 229Th 
through the fast neutron irradiation of 230Th at Lawrence Berkeley National Laboratory. For this 
thesis work, the objectives are to: 
1.) Experimentally evaluate the effective neutron cross section of 229Th in HIFR and 
2.) Determine the most effective method for preparing 230Th targets for accelerator-generated 




CHAPTER 3: MATERIALS AND METHODS 
 
 3.1. Description of Facilities 
For both projects, the target preparation and chemical separation work was performed in both 
radiological and non-radiological lab facilities in Building 4501 at Oak Ridge National 
Laboratory. The High Flux Isotope Reactor (HFIR) at ORNL was used to irradiate the 229Th 
target sample for cross-sectional analysis. HFIR operates at 85 MW and produces one of the 
highest steady-state thermal and cold neutron fluxes of any research reactor in the world [45]. It 
is a beryllium-reflected, light water-cooled and moderated, flux trap type reactor that uses highly 
enriched uranium-235 as fuel and produces an average thermal neutron flux of 2.3 X 1015 n/cm2-
s [45]. It contains thirty target positions in the flux trap located in the center of the core, 
including the hydraulic tube (location utilized for the 229Th target irradiation,) which allows for 
insertion and removal of samples while the reactor is in operation. It also contains six peripheral 
target positions located at the outer edge of the flux trap, several vertical irradiation facilities of 
various size located throughout the beryllium reflector, two pneumatic tubes in the beryllium 
reflector used for neutron activation analysis, and two slant access facilities located on the outer 
edge of the beryllium reflector [45]. 
For the second project described in this thesis, methods of preparation were tested for a target 
to be irradiated with fast neutrons in the 88-Inch Cyclotron at Lawrence Berkeley National 
Laboratory (LBNL.) This facility has both light- and heavy-ion capabilities that can produce 




MeV, 170 MeV, and 130 MeV, respectively [46]. The cyclotron can produce fast neutrons with 
fluxes up to 1.0 X 108 neutrons/cm2-s via thick-target breakup of deuterons on a beryllium target 
in the cyclotron vault [46] [47]. Beam-time is available for this irradiation from the 500-hour 
annual allocation reserved for the nuclear data program.  
3.2. Gamma-ray spectroscopy 
Gamma-ray spectroscopy was used frequently during all stages of these two projects to 
quantify the activity of each isotope of interest. Each measurement was conducted on a Canberra 
Model GC2020 high purity germanium (HPGe) detector which was connected to a computer-
based multi-channel analyzer (MCA) that utilized Canberra Genie 2000 software. γ-ray 
spectroscopy was performed to determine activities of each fission product. For 229Th fission 
product analysis, each fission product was corrected for decay back to end of bombardment 
(EOB) via Equation 1.  
𝐴(𝑡) = 𝐴𝑜𝑒
−𝜆𝑡        (1)  
Spectra were counted for anywhere from 5 minutes to 60 hours for long half-lived or 
greatly decayed radioisotopes. Over 100 counts were performed for the analysis of these two 
projects. When possible, multiple γ-ray peaks were used to quantify the activity of each 
radioisotope of interest through a weighted average method; however, often only one or two 
energy peaks (the most intense) from each radionuclide were used to estimate the activity due to 
the complicated spectrum of the fission products and their decay daughters. Figure 3 shows an 




after 36 hours of counting. Table 1 summarizes the principle γ-ray emissions associated with 
each radionuclide used to assay each sample of interest [22].
 
Figure 3: Gamma-ray spectra of a Th-230 sample with decay daughters prior to preparation for fast 
neutron irradiation 
 
Table 1: Principle gamma-ray emissions used to assay radionuclides in these experiments 
Radionuclide Half-life Eγ (keV) Iγ (%) 
95Zr 64.032 d 756.7 55.4 
131I 8.025 d 364.5 81.5 
132Te 3.204 d 228.2 88.1 
137Cs 30.08 y 661.7 85.1 
140Ba 12.753 d 537.3 24.4 
141Ce 32.511 d 145.4 48.4 
144Ce 284.91 d 133.5 11.1 
147Nd 10.98 d 91.1 27.9 
213Bi 45.59 m 440.5 26.1 
221Fr 4.9 m 218.0 11.6 
229Th 7932 y 193.6 4.41 
230Th 7.54x104 y 67.7 0.38 
232Th 1.4x1010 y 238.6 43.6 
  (212Pb)  
233Pa 26.975 d 311.9 38.5 
230Th (67.7 keV, 0.38%)
230Th (143.9 keV, 0.049%) 
230Th (186.1 keV, 0.009%) 
230Th (214Pb, 295.2 keV, 18.4%) 
230Th (214Pb, 351.9 keV, 35.6%) 






























3.3. 229Th cross section experimental evaluation procedure 
The experimental procedure for 229Th effective neutron fission cross section was carried out 
at ORNL in summer 2018. It involved the use of γ-ray spectroscopy, ion-exchange 
chromatography, fission yield activity calculation estimates, neutron irradiation in the hydraulic 
tube of the High Flux Isotope Reactor, and cross section and associated error calculations. Two 
229Th targets were initially prepared; however, one target broke during the sealing process, so the 
rest of the experiment was carried out with the single target sample.  
3.3.1. 229Th sample preparation for HFIR irradiation 
To prevent contamination when working with radioactive materials, protocol requires all 
radioactive material to be double-contained. Therefore, five quartz ampules and three finned 
aluminum rabbits were cleaned in preparation according to the MRP-49 Rev. 1 procedure [48]. 
All the current 229Th stock located within the Nuclear and Radiochemistry group at ORNL was 
counted on a HPGe gamma spectrometer. In total, 16 UThX samples were each oriented to 
reduce the detector dead time below 5% and counted for five minutes to estimate the total 
thorium-229 activity and to evaluate each sample vial for other thorium contaminants. Each vial 
that contained traces of other thorium isotopes such as 232Th were not used during the separation 
process since isotopes of the same chemical element are not easily separated. We completed 
calculations to estimate the activity (in µCi) of each sample based on the detector geometry, 
detector efficiency derived from calibrations completed using a National Institute of Standards 
and Technology (NIST) gamma ray source, and intensity for each energy peak of interest (Table 




unique energy peak and Canberra γ-ray spectroscopy results where A represents the activity of 
the radioisotope in becquerels, CPS is the number of counts seen by the HPGe detector per 
second, Eff is the efficiency of the detector based off of the sample geometry and distance from 





       (2) 
Activity in becquerels can easily be converted to activity in µCi by Equation 3.  
𝐴(𝜇𝐶𝑖) = 2.7𝑥10−5 × 𝐴(𝑏𝑞)    (3) 
Activity can also be converted to mass, m in grams by using the relationships in Equations 4 and 
5, where A is the activity in becquerels, λ is the decay constant, N is the number of atoms, NA is 
Avogadro’s number, and M is the atomic mass number.  




∗ 𝑀          (5) 
3.3.2. Ion exchange chromatography for 229Th isolation 
The six largest thorium samples were run through two 200 µL columns designed with 
glass wool and MP1 200-400 resin. One column was washed with HCl and the other with HNO3.  
20 drops of 8M nitric acid were added to each of the six thorium samples and the solutions were 
pipetted into the nitric column. In this step, the larger thorium isotope remains in the column 




ensure entire separation. Then, 40 drops of 10M HCl was added to strip the thorium isotope from 
the column and test for its purity. This step was repeated twice more with another 20 drops of 
10M HCl and then 0.5 mL of distilled water, respectively. The dilute thorium solution was then 
loaded onto the HCl column. 200 µL of 0.1M HNO3 was then passed through the column to 
separate the thorium from any remaining impurities. After each purification step, the products 
were counted on the HPGe detector to verify accurate separation. The purified 229Th was 
combined and deposited into cleaned quartz glass ampules to create two ~32.8 µCi pure ThO2 
target samples.  
3.3.3. Target ampule and aluminum rabbit sealing 
Both glass ampules were taken to a glove box for sealing; however, one ampule was 
broken during the heat-sealing process, so the rest of the experiment was performed with the 
single sample. The broken pieces with 229Th were safely stored in the glove box until the 
material was needed by staff for additional research experiments. The remaining ampule was 
wrapped in an aluminum foil and placed in one of the clean, finned aluminum rabbits. The 
sample was then transported to the welding facility at ORNL, where the rabbit was welded and 
thoroughly leak tested to ensure all safety requirements were met according to HFIR safety 
specs.  
3.3.4. Fission yield estimates and irradiation 
While preparing the sample, we completed fission yield calculations to estimate the 




irradiation time. This was done to approximate the activity of the sample post-irradiation for 
radiation safety and handling purposes and to determine an acceptable length of irradiation 
needed to complete this experimental analysis. Calculations were also completed to estimate the 
number of counts per second (CPS) that the HPGe detector will perceive so that we could have a 
rough estimate of what to expect.  
To perform these calculations, we used the recommended values of the cumulative 
fission product yields for thermal fission in 229Th given in a 1977 paper by E. Crouch (Table 2) 
[49]. Equation 6 was used to calculate the estimated activities A (Bq) for each fission product, 
where N is the total number of 229Th atoms, 𝜎 is the 229Th fission cross section, 𝜙 is the flux of 
the reactor, λ is the decay constant, t is the irradiation time, and FY is the fission yield.   
𝐴 = 𝑁𝜎𝜙(1 − 𝑒−𝜆𝑡) ∗ 𝐹𝑌        (6)  
Table 2: Probable fission products and yields for thermal neutron irradiation of Th-229 [22] [49] 
Nuclide Half-life Fission Yield (%) Error (%) 
As-77 38.83 h 0.0933 15.0 
Ge-78 88.0 m 0.052 15.0 
Br-83 2.374 h 6.32 8.5 
Br-84 31.76 m 10.9 3.5 
Br-85 2.90 m 10.8 5.0 
Br-87 55.65 s 9.75 5.0 
Rb-88 17.8 m 8.60 11.4 
Sr-89 50.56 d 8.89 14.9 
Sr-90 28.9 y 8.14 12.7 
Y-91 58.51 d 7.10 14.1 
Y-92 3.54 h 6.40 8.0 
Y-93 10.18 h 4.40 6.0 
Zr-95 64.03 d 2.37 10.6 





Table 2 (cont.) 
Nuclide Half-life Fission Yield (%) Error (%) 
Mo-99 2.75 d 0.153 8.3 
Ru-103 39.25 d 0.00621 75.7 
Ru-105 4.44 h 0.00819 53.2 
Ru-106 371.8 d 0.0126 25.9 
Pd-109 13.7 h 0.00777 26.8 
Ag-111 7.45 d 0.0209 4.7 
Pd-112 21.04 h 0.0203 12.6 
Ag-113 5.37 h 0.0154 14.8 
Cd-115 53.46 h 0.0185 4.7 
Cd-117 2.49 h 0.0165 6.0 
Cd-118 50.3 m 0.0174 5.0 
Sn-121 27.03 h 0.0740 5.0 
Sn-125 9.64 d 0.0371 14.1 
Te-127 9.35 h 0.00858 56.9 
Te-129 69.9 m 0.122 7.0 
I-131 8.03 d 0.648 15.5 
Te-132 3.204 d 1.20 9.6 
Te-133 12.5 m 3.04 14.0 
Te-134 41.8 m 5.91 6.4 
Te-135 19.0 s 5.52 10.3 
Te-136 17.63 s 6.03 5.0 
Cs-137 30.08 y 7.05 9.0 
Cs-138 33.41 m 8.00 5.0 
Cs-139 9.27 m 8.96 5.0 
Ba-140 12.75 d 10.4 17.0 
Ce-141 32.5 d 8.07 3.4 
Ce-142 >5x1016 y 5.72 22.5 
Ce-143 33.04 h 6.13 26.2 
Ce-144 284.91 d 6.38 16.9 
Ce-145 3.01 m 3.21 26.6 
Ce-146 13.49 m 2.14 5.0 
Pr-147 13.4 m 1.83 15.0 
Pr-148 2.29 m 1.07 5.0 
Pr-149 2.26 m 0.710 15.0 
Pr-150 6.19 s 0.180 5.0 





The activities were corrected for decay (Equation 1), and it was assumed the sample 
would be returned for analysis between 7-14 days post-EOB. In this case, 𝐴𝑜 is the activity at 
EOB, 𝜆 is the decay constant, and t is the decay time following EOB. We assumed the sample to 
be counted on the HPGe in Building 4501 Room 311 at a geometry height of 20 cm, so the 
expected CPS seen by the detector could be evaluated (equation 2.) Table 3 summarizes the 
parameters used during the irradiation of our 229Th sample.  
Table 3: Irradiation parameters for Th-229 cross section analysis 
Irradiation Parameters 
Sample ID NM-855 
Target material Th-229 
Mass (mg) 0.165 
Fission cross section (b) 30 
Position in reactor 7 
Flux (n/cm2s)  1.65E+15 
Irradiation time (hr) 12 
 
3.3.5. Post-irradiation processing 
 After irradiation in HFIR, the sample was given two weeks to cool on site at the reactor 
facility and then shipped back to Building 4501 for processing. Upon arrival, radiochemistry 
staff removed the rabbit and ampule from its shipping containment vessel via manipulators 
inside the hot cell facility and separated the ampule from its rabbit casing. Due to higher dose 
rates of radiation than expected, we were not able to count the whole ampule directly on the 
HPGe detector, even on the highest counting shelf. Therefore, we transferred the ampule to the 




Once placed in the glove box, the outside of the target was cleaned with 8M HNO3 and 
rinsed with distilled water. Dose rates of the target were measured during transfer in the lead pig 
and while in the glove box using handheld scintillation and alpha spectrometers. The ampule was 
then cut open and 5 drops of 10M HCl were deposited into both pieces of the cut ampule. The 
top and bottom pieces of the ampule were rinsed with a total of 1mL of 10M HCl and combined 
as the target solution in a scintillation vial. Air was gently bubbled through the solution to ensure 
homogeneous mixing.  
100 µL of the 1mL target solution was taken and deposited in a separate vial to represent 
a fraction of the total target solution and allow for more manageable γ-ray counting. This vial 
was labeled as Target Solution. Another MP1 ion exchange chromatography column was 
prepared and placed in the glove box system to run column separations of the target solution. 
The column was run once with the target solution but determined to be unnecessary due to time 
restraints and counting purposes. Distilled water was run through the column to remove any 
fission products caught in the resin. We labeled this fraction MP1 ww. The bottom piece of the 
ampule (the piece containing the majority of the 229Th target) was further rinsed separately with 
5 more drops each of concentrated HCl and NH4OH to further remove the fission products from 
the glass. The vials of each were labeled as bot-HCl and bot-NH4OH, respectively. The bottom 
piece of the ampule was further broken into 5 smaller pieces due to large amounts of fission 
products embedded in the glass despite earlier attempts to remove them. These glass ampule 
pieces were labeled as Bot-A, Bot-B, Bot-C, Bot-D, and Bot-E. In total, 11 fractions of the target 






Table 4: Fractions of target ampule separated and prepared for gamma-ray counting 
Fraction Label Description 
1 Target Solution 10% of whole target solution 
2 Top top piece of ampule 
3 Bot-A broken piece of bottom part of ampule 
4 Bot-B broken piece of bottom part of ampule 
5 Bot-C broken piece of bottom part of ampule 
6 Bot-D broken piece of bottom part of ampule 
7 Bot-E broken piece of bottom part of ampule 
8 Bot-HCl HCl rinse of bottom piece of ampule before broken 
9 Bot-NH4OH NH4OH rinse of bottom piece of ampule before broken 
10 MP1-WW distilled water rinse of column 
11 Column MP1 resin column 
 
3.3.6. Post-irradiation analysis 
 We counted each target fraction on the HPGe γ-ray spectrometer for one hour and 
quantified the activities of the radionuclides in each sample utilizing a weighted average method 
and correcting for decay (Equations 1 and 2). Weighting factors (𝑤𝑖) for each γ-ray were 
determined by Equation 7 and used to evaluate the weighted activities and uncertainty (𝑥𝑖) in 
percent of the activity values for each radionuclide (Equation 8), where 𝜎𝑖 is the uncertainty 















Knowing the weighted activities associated with each radionuclide for each of the 11 
target fractions and accounting for the dilution factor of the target solution, the activities were 
summed to determine the total activity of the target at EOB. Equation 4 could then be used to 
back-calculate the effective neutron fission cross section corresponding to each fission product 
evaluated. We then averaged these values and determined the associated propagated error to 
resolve a value for total effective neutron fission cross section of 229Th. 
3.4. 230Th target preparation 
In addition to performing an experiment to determine the fission cross section of 229Th for 
isotope production, we also began the beginning phases of testing a method for producing 229Th 
from the fast neutron irradiation of 230Th. This process involved the quantification of 230Th in the 
laboratory via γ-ray spectroscopy, 232Th stock concentration and chemical analysis, and three 
methods for testing the uniform deposition of thorium stock onto filter paper, aluminum foils, 
and in a school glue matrix. We quantified each sample prepared via γ-ray spectroscopy and 
utilized photostimulated luminescence to determine the distribution of radioactivity across each 
sample.  
3.4.1 230Th quantification 
230Th only exists naturally from the 238U decay chain with an abundance of 0.02% and 
half-life of 75,400 years [22]. Therefore, enriched 230Th for experimental purposes is limited. 
ORNL had previously completed experiments with highly enriched 230Th isotope, so the first 
step in our experiment was to filter through past 230Th samples and quantify the total amount of 




for a minimum of 2 hours to reduce the error associated with each γ-ray energy peak to less than 
1.0%.  
The solution sample with the largest amount of 230Th was chosen for our experiment. 
Since the solution containing the thorium isotope was unknown, this sample was fully dried 
down using low heat on a heat plate and heat lamp. Then, 5 mL of 0.1M HNO3 was added to the 
vial and swirled until the thorium was fully dissolved. The solution was dried down once more to 
ensure no other ions were present. Then, 1 mL more of 0.1M nitric acid was added to bring the 
solution up to a known concentration and to simplify future calculations.  
3.4.2 232Th chemical analysis 
Before performing any experiments with the limited 230Th sample, each method was 
tested using the more abundant 232Th stock as a surrogate radionuclide. Approximately 1.0 gram 
of 232Th in the form of Th(NO3)4 • 5H2O (total mass 2.471 grams) was prepared for us by a 
chemist in the group performing other experiments with the thorium isotope. Mass ratios were 
calculated to verify the 1.0 gram value. Since 232Th has a half-life of 1.40 x 1010 years, the 
activity and mass of the material could not be directly measured by the γ-rays emitted from the 
decay of the isotope, but rather by quantifying the amount of the shorter-lived daughter, 227Th 
(T1/2 = 18.7 days,) to determine the activity of 232Th throughout the experiments [22].  
In a non-radiological laboratory, we tested the deposition of a NaCl solution with 
equivalent concentration to that of the 230Th solution onto 15mm diameter circular pieces of filter 




LBNL staff for irradiation in their particle accelerator. To avoid oversaturation, we determined a 
solution concentration of 140 mg/mL was a reasonable concentration to work with for practicing 
deposition techniques with 232Th stock solution. The general formula used to calculate these 
concentrations is summarized by Equation 9.  
  𝑐1𝑣1 = 𝑐2𝑣2      (9) 
To achieve this concentration, 7.18 mL of 0.1M HNO3 was added to the dried 1.0 gram 
232Th stock sample, swirled for one minute, and left over the weekend to homogenize. The final 
stock solution was quantified via γ-ray spectroscopy, and the time and day was noted as the 
standard reference date for activity calculations.  
3.4.3. 232Th trial deposition on filter paper 
We chose to test our ability to deposit thorium masses of 5 mg, 10 mg, 20 mg, 30 mg, 40 
mg, and 50 mg onto filter paper first. The pieces of filter paper were organized in a petri dish and 
the experiments were carried out in a project-designated fume hood of a radiological laboratory 
in Building 4501. Utilizing concentration ratios, we calculated the total volume of thorium stock 
solution needed to equate those masses (Table 5). To control the amount of liquid solution 
during deposition so as not to oversaturate the filter paper material, we dispensed the solution 
using a calibrated pipette in several 12 µL drops. The targets were slowly heated on a hot plate 
and under heat lamp to reduce drying time, which ranged anywhere from 1 to 4 hours depending 
on the mass of the sample. We had to be careful to allow for adequate drying time in between 




previous samples dried for the most efficient use of time. Once dry, the samples were double-
contained and counted on the HPGe detector to compare the expected vs. actual thorium mass 
deposited.  
Table 5: Th-232 mass and equivalent volume deposition onto filter paper summary 
232Th Mass 
(mg) 
Number of pipette 
transfers (x12 µL) 
Total solution 
volume (µL) 
5 3 36 
10 6 72 
20 12 144 
30 18 216 
40 24 288 
50 30 360 
 
3.4.4 232Th trial deposition on aluminum foils 
A similar method was performed for thorium deposition onto aluminum foils as was done 
for deposition onto filter paper. Since the aluminum was not absorbent like the filter paper, we 
were able to dispense more of the stock solution per drop (36 µL instead of 12 µL) without the 
risk of supersaturating the target material (Table 6). This reduced the time for full deposition and 
drying of all the samples by more than half.  
Table 6: Th-232 mass and equivalent volume deposition onto aluminum foil summary 
232Th Mass 
(mg) 
Number of pipette 
transfers (x36 µL) 
Total solution 
volume (µL) 
5 1 36 
10 2 72 
20 4 144 
30 6 216 
40 8 288 





For these samples, we also tested the inclusion of a layer of Kapton tape over the 
deposited 232Th after drying to lock out air and moisture and to help prevent the sample from re-
hydrating over time, which was an issue observed from early samples created. Kapton tape is a 
polyimide film known for its unique combination of electrical, thermal, chemical and mechanical 
properties that allows it to withstand extreme temperatures, vibrations, and other harsh 
conditions [50]. It was used in previous fast neutron irradiation experiments with negligible 
impact on results [51]. 
3.4.5 232Th trial deposition into school glue matrix 
The third unique method we tested for creating 232Th targets was through distributing and 
drying the radionuclide solution in a school glue thin film matrix. For this method, we allowed a 
small (1” x 1”) piece of parafilm soak in toluene for approximately 1 hour to dissolve the 
paraffin from the film. The paraffin was used to coat the inside of a small 15mm diameter glass 
cylindrical ring to prevent sticking. A small piece of parafilm was stretched around the bottom of 
the glass cylinder. We then removed the needles from two plastic 1 mL syringes and connected 
the plastic tips together with 1-inch-long piece of similar diameter Tygon tubing.  
650 µL of Darice school glue was added to one syringe and tapped excessively to remove 
any bubbles. In the other syringe, 335 µL of thorium-232 nitrate solution was carefully added. A 
drop of PAR reagent was also added as a color indicator for sufficient mixing. We then used the 
connected syringe system to pass the two solutions back and forth between the syringes until the 




the Th(NO3)4 glue solution into the glass cylinder on the parafilm bottom and left the thorium 
glue matrix to dry overnight.  
3.5. Phosphor imaging 
The radioactivity distribution of each sample target was tested using a Cyclone Plus 
Storage Perkin Elmer Phosphor System. This imaging system utilized OptiQuant9 software for 
image acquisition, analysis, display, and archiving [52]. Reusable storage phosphor screens 
capture and store the radioactivity of samples exposed to the film, where then each screen can be 
scanned by a helical-scanning laser system focused to less than 50 µm. A high resolution 
digitized image with quantitative data in image file format is acquired through the unique 
confocal optics of the system, which displays the image on the screen that can be analyzed with 
OptiQuant software and printed, exported, or archived for future reference or analysis [52].  
For our experiments, we utilized the phosphor imaging system to study and quantify the 
uniformity of our radioactive 232Th samples and track their stability over time. To acquire each 
image, we turned to lights off in the laboratory to reduce background light exposure to the 
phosphor screen and carefully placed the screen over the double-bagged sample to be sealed in a 
light-tight casing. The samples were exposed to the screen for approximately 5-11 minutes 
depending on mass size. With the room still dark, we quickly removed the phosphor film and 
placed in the Cyclone Plus Storage Phosphor System where the system scanned the screen and 
produced high resolution digitized images. Several 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, and 50 




compare how mass size, deposition techniques, and time have an impact on the uniformity and 






CHAPTER 4: 229TH NEUTRON FISSION CROSS-SECTION 
RESULTS AND DISCUSSION 
 
4.1. Target preparation results 
 16 UThX samples were counted on the HPGe detector to determine 229Th quantities and 
evaluate each sample vial for other thorium contaminants. Table 7 summarizes these results. 193 
keV (4.41%) and 211 keV (2.8%) correspond to the most intense γ-rays emitted from the decay 
of 229Th and 238 keV (212Pb, 43.6%) and 583 keV (208Tl, 85.0%) are the most intense γ-rays 
emitted from radionuclides in the 232Th decay chain [22].   





Time (%)  
CPS Activity (uCi) Average 
(uCi) 
238/583 
keV? 193 keV 211 keV 193 keV 211 keV 
1 20 1.7 13.5 7.77 4.60 4.16 4.38 no 
2 20 7.5 54 38.3 18.39 20.50 19.44 no 
3 20 13.36 140 75.6 47.67 40.47 44.07 no 
4 60 0.68 5.68 3.9 12.89 13.92 13.41 no 
5 5 0.03 0.225 0 0.01 0.00 0.00 no 
6 5 0.23 1.95 1.34 0.07 0.08 0.08 no 
7 20 1.81 14.3 7.47 4.87 4.00 4.43 no 
8 20 3.62 31.3 20.3 10.66 10.87 10.76 no 
9 20 0.45 3.49 2.23 1.19 1.19 1.19 no 
10 30 5.13 54.1 28.4 37.26 30.77 34.01 no 
11 20 1.52 13.2 8.38 4.49 4.49 4.49 no 
12 20 1.02 8.95 5.11 3.05 2.74 2.89 no 
13 60 3.59 20.7 17.2 46.98 61.38 54.18 yes 
14 60 1.25 10.1 5.35 22.92 19.09 21.01 yes 
15 20 2.75 27.4 15 9.33 8.03 8.68 no 





Since sample 10 was already placed in a quartz ampule, we chose this sample as one of 
our targets and combined samples 1, 2, and 8 using 8M HNO3 to produce another target of 
similar activity. Both target samples were run through a series of column separations to remove 
the daughter nuclides so that only 229Th was present. We counted each of the final target samples 
overnight to more accurately quantify their activities and calculate their respective masses using 
Equations 4 and 5 (Table 8). Note: the 0.146 mg mass sample broke during the sealing process, 
so the rest of the experiment was carried out using only the 0.165 mg mass sample.  











229Th for fission 1 29.1 1.08E+06 2.77E-12 3.89E+17 0.146 
229Th for fission 2 32.8 1.21E+06 2.77E-12 4.38E+17 0.165 
 
4.2. Fission yield estimates 
Using Equation 6 and the irradiation parameters given in Table 3, we estimated the 
activity of the 0.165 mg mass sample fission products at EOB after varying irradiation times 
(Figure 4.) We assumed the fission yields given in the Crouch et al. paper and the currently 
standardized fission neutron cross section of 30 barns to perform these calculations. If our 
hypothesis that the fission cross section of 229Th is much smaller than the current standard is 
correct, then we would expect to detect lower activity values for each of these fission products 
after the experiment.  These calculations also show that we should expect to see the highest 
activities of 135Xe, 133Xe, 132Te, and 140Ba. These mass numbers correlate to the second hump in 




radionuclides with mass numbers around 83-89 as well, but since many of those nuclides have 
half-lives on the order of seconds to a few hours, they would not be detectable by the time we 
performed analysis on the target due to decay. Therefore, the activities were not evaluated in 
these calculations.  
 
Figure 4: Project activity estimates of fission products as a function of irradiation time. These values are 
estimated based from the half-life of each radionuclide, an assumed fission cross section of 30 barns, the 
fission yields given in Crouch et al., the most intense gamma ray energy peak of each nuclide used and 
counted on the HPGe detector at a 20 cm geometry.   
 
From our activity estimates and what we previously understood about the fission products 
and manageable activity amounts at that time, we chose to irradiate our 0.165 mg sample for 12 
hours (0.5 days.) In retrospect, as described later, this irradiation time was still too long for 
accurate γ-ray counting and required us to perform post-irradiation chemical processing that 







































however, we also calculated the activity (in counts per second, CPS) expected for each fission 
product at various times post-irradiation (Figure 5.) These values were estimated with Equations 
1 and 2 using the most intense γ-ray energy peak associated with each fission product and 
assuming the target would be counted on shelf 20 cm of HPGe detector located in the 3rd floor 
radiation laboratory of Building 4501.  
 
Figure 5: Projected count rate of fission products at various times post end of bombardment (EOB.) 
These values are estimated based from the half-life of each radionuclide, an assumed fission cross section 
of 30 barns, the fission yields given in Crouch et al., the most intense gamma ray energy peak of each 
nuclide used and counted on the HPGe detector at a 20 cm geometry.   
  
These results show that 135Xe should have the highest activity immediately after end of 
bombardment; however, it quickly decays to manageable quantities within one week of 





































remains the most radioactive fission product at 14 days post-EOB. Our 229Th target was 
delivered back to Building 4501 approximately two weeks after EOB and the processing and 
analysis occurred over the next 1-2 weeks. Therefore, 95Zr/95Nb, 131I, 133Xe, 140Ba/140La, 141Ce, 
and 147Nd were some of the most prevalent fission products to analyze due to their ~8 to 60-day 
half-lives. Other longer-lived radioisotopes such as 137Cs and 144Ce were also produced but not 
as easily detectable due to the high activities of their shorter-half-lived counterparts.  
 
4.3. Post-irradiation processing and analysis 
 When the target returned to Building 4501 post EOB, the ampule was removed from the 
aluminum rabbit casing with manipulators inside the hot cells and transported to the glove box 
facility within the building in a lead pig. Table 9 summarizes the dose rates measured using a 
handheld scintillation spectrometer immediately after transfer. These dose rates are general 
estimates visibly observed from the spectrometers. Before placing into the glove box, we 
estimated the dose rate of the target ampule to be ~600 mrem per hour on contact, proving it to 
be a sample difficult to analyze without proper processing and shielding.  
Once in the glove box facility, the ampule was carefully cut open into two pieces 1/3 
from the top. Both pieces were rinsed with 8M HNO3 to remove the thorium target and fission 
products and transported into a new vial. Through the glass shielding of the glove box, we 
measured the dose rate of the target solution vial to be approximately 160 mrem per hour and the 
dose rates of the top and bottom pieces of the ampule to be 13 mrem and 60 mrem, respectively. 




solution vial, we re-measured the dose rates with the portable spectrometer, expecting an 
increase in the target solution dose rate and decrease in the ampule dose rates; however, similar 
results were measured, showing the nitric acid was not strong enough to remove the fission 
products embedded in the glass.  
 






1 14 top of pig with ampule inside 
2 600 no shield on contact 
3 11 
detector on glove box glass shield with ampule inside center of 
glove box 
4 15 
Detector on glove box glove with ampule inside center of glove 
box 
5 7 area background 
6 160 
first HNO3 rinse of ampule close contact though glass glove 
box shield 
7 60 
bottom part of ampule after first rinse close contact though 
glass glove box shield 
8 13 
top part of ampule after first rinse close contact though glass 
glove box shield 
9 150 
second HNO3 rinse of ampule combined with first close contact 
though glass glove box shield 
10 65 
bottom part of ampule after second rinse close contact though 
glass glove box shield 
11 10 
top part of ampule after second rinse close contact though glass 
glove box shield 
 
Concentrated hydrochloric acid and ammonium hydroxide were each separately added to 
the ampule pieces and allowed to soak for 1-4 hours to remove the fission products with some 
success, but many of the fission products were still deeply imbedded in the glass. Each of these 
solutions were separated and labeled in additional vials. Because of these results, we 
contemplated adding hydrofluoric acid to remove the fission products from the glass but chose 




ampule up into five smaller fragments and sealed them into individual vials for analysis. 
Performing this additional processing step by opening the ampule and transferring the target 
solution to additional vials was necessary but unideal due to the potential loss of fission products 
in the gaseous form such as 103Ru and 131I and pipette losses.  
Each component was safely removed from the glove box facility, checked for indications 
of contamination and counted on the HPGe γ-ray spectrometer, where we calculated the average 
weighted activities of each detectable fission product based on the associated γ-ray energy peaks 
and intensities, sample geometry, and efficiency (Table 10.) During our analysis, we detected 
relatively large amounts (1.6 mCi) of the radionuclide protactinium-233 (T1/2=26.9 days.) This 
meant that our initial 229Th was not pure, but instead included trace amounts of 232Th that were 
then activated upon neutron bombardment. The 232Th was not detected during our target 
preparation due to its long half-life (1.4 x 1010 years) and our short ~5-minute counts. 
Furthermore, when we prepared the target, we calculated a total activity of 32.8 µCi for 
229Th; however, we calculated approximately 45.7 µCi of 229Th in total for all the ampule pieces 
counted post-irradiation, which is not possible. The target preparation and post-irradiation 
calculations were double-checked to confirm these values. It is not determined which value is 
incorrect; however, for future irradiation experiments such as this, we learned from this 
experience that a mass spectrometry analysis of a sample before experimentation is critical for 
validating results. Because we did not send our sample in for a mass spectrometry analysis and 
we cannot get our mass results of the initial target to match before and after irradiation within a 
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Weighted Average of Activity (uCi at EOB) Sum 
(µCi at 
EOB) 
Target             
Th-229 1.68E+01 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 1.64E-01 2.68E-02 6.96E-01 2.80E+01 4.57E+01 
Th-232/ 
Pa-233 3.73E+02 2.66E+01 3.15E+01 1.39E+01 3.35E+01 1.64E+01 5.78E-01 1.88E+00 2.73E+00 1.74E+02 9.52E+02 1.63E+03 
             
Fission             
Y-91 0.00E+00 0.00E+00 0.00E+00 3.50E+01 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 4.82E+00 0.00E+00 3.98E+01 
Zr-95 2.83E+01 3.34E+00 4.73E+00 2.55E+01 6.32E+00 3.13E+00 7.76E-02 2.53E-01 6.13E-02 6.82E+00 8.52E+01 1.64E+02 
Nb-95 1.83E+01 2.13E+00 3.95E+00 2.05E+01 5.13E+00 2.66E+00 6.49E-02 1.19E-01 7.29E-02 1.07E+01 3.79E+01 1.02E+02 
Ru-103 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 4.97E-02 0.00E+00 4.97E-02 
I-131 4.99E+01 5.60E+00 6.15E+00 3.54E+01 8.34E+00 3.89E+00 9.96E-02 1.34E-01 6.99E-02 9.45E+01 0.00E+00 2.04E+02 
Te-132 2.83E+02 2.09E+01 0.00E+00 3.07E+01 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 3.34E+02 
Cs-137 5.66E-01 5.11E-02 5.17E-02 3.10E-01 6.28E-02 3.48E-02 9.24E-04 3.60E-02 1.25E-02 3.42E-02 0.00E+00 1.16E+00 
Ba-140 5.35E+02 3.77E+01 5.53E+01 2.99E+02 7.71E+01 3.55E+01 9.31E-01 1.26E+00 3.08E-01 3.56E+01 1.02E+03 2.10E+03 
Ce-141 1.83E+02 1.35E+01 2.01E+01 1.05E+02 2.73E+01 1.33E+01 3.39E-01 6.06E-01 1.51E-01 1.38E+01 3.59E+02 7.36E+02 
Ce-144 2.40E+01 1.81E+00 2.75E+00 1.49E+01 4.14E+00 1.75E+00 4.94E-02 9.34E-02 2.10E-02 1.70E+00 5.00E+01 1.01E+02 





experiment. Performing mass spectrometry of the sample would also expose the presence of 
232Th and any other contaminants in the target prior to irradiation.  
4.4. Effective fission neutron cross section  
Despite these setbacks, we used our calculated weighted activity values and associated 
errors for each radionuclide to carry out the cross section calculations and determined the 
effective neutron fission cross section of 229Th to be 8.36 ± 0.37 barns. This value is less than 
28% of the current conservative standard neutron fission cross section value of 30 barns, which 
is a great result that validates our proposed hypothesis. Since a large cross section also produces 
more heat in a nuclear reaction and limits the size of the initial target for 229Th production, the 
lower value would allow for a larger 226Ra and subsequent higher production rate of 229Th per 
irradiation.  
 We also plotted the percent fission yields of our data as a function of mass number 
compared to the data produced by Crouch et al. (Figure 6.) Our results showed that similar 
fission products were generated as expected and followed a related trend to that of Crouch et al. 
As anticipated, many of the short-lived and gaseous fission products were either decayed away 
or escaped before γ-ray counting, but the results that we did acquire are still promising.   
According to ENDF/B-VII data, however, the 229Th fission cross section is approximately 
1/ν in the thermal range [53]. This means that even very small differences and fluctuations in the 
neutron energies can results in significant variations in the cross section measurement. Our 
analysis assumed a constant neutron flux of 1.65 x 1015 n/cm2s. A constant flux like this is most 




monitor with the target during irradiation and perform additional calculations to account for 
these variations in the neutron energy spectrum.  
 
Figure 6: Experimental percent fission yield plot of this work compared to the results produced from 
Crouch et al. 
 
Although our fission cross section results are unreliable due to erroneous 229Th recovery 
and minimal fission product data, we learned a lot from this experiment and will use this 
newfound information as a reference point for future 229Th fission cross section experiments. For 
example, we plan to repeat the experiment using multiple smaller (~5 µCi) samples instead of 




eliminate the need to chemically process the target after irradiation and allow for more accurate 
and representative data collection. We also will perform mass spectrometry on the samples prior 
to irradiation to verify the content and mass values of each target as a benchmark. Furthermore, 
during our target dissolution processing, we did not expect to observe the fission products so 
deeply embedded in the glass after only a 12 hour irradiation period. This effect had an impact 
on our results as we were forced to break the glass into smaller pieces to get the activities to a 
more manageable level. Therefore, we plan to perform an irradiation experiment by drying a 
thorium solution onto aluminum foil and completely dissolving the target after irradiation to 









5.1. 230Th and 232Th stock quantification 
 Like with the 229Th experiment, we quantified the 230Th samples in the laboratory via γ-
ray spectroscopy. We chose to work with one particular sample with a mass of ~60 mg (1.24 
mCi.) This sample was prepared by drying down under a heat lamp on a hot plate, adding 0.1M 
nitric acid, drying down again, and bringing the sample back up to a known volume with 0.1M 
HNO3. The preparation of the actual 230Th target for fast neutron irradiation was completed by 
ORNL staff and a University of Tennessee – Knoxville Nuclear Engineering graduate student 
after the results for this thesis were finalized and therefore will not be described in this thesis 
document. 
 The rest of the work for this project was performed with a 232Th stock solution as a 
surrogate for 230Th due to its higher abundance. Because of 232Th incredibly long half-life (1.4 x 
1010 years,) we quantified its amount by determining the activity of  227Th and using the isotope 
ratios in the sample. By γ-ray spectroscopy, we determined the mass and activity of this stock 
solution to have a weighted activity of 30.4 µCi of 227Th and respective mass of 1.0 grams for  




time for a standard form of comparison when calculating the activities of each of our thorium 
stock samples. 
5.2. 232Th deposition on filter paper 
 We tested our method of depositing our thorium stock solution onto 1.5 cm (15 mm) 
diameter filter paper first. We wanted to determine how effective our method of mass deposition 
is for producing accurate and uniform thorium targets. Table 11 and Figure 7 summarize this 
comparison. Overall, the results are quite promising with yields very close to 100% and a fitted 
R2 value of 0.999.  
 
Table 11: Deposition results for thorium stock solution onto filter paper 







S0.5 5.0 5.0 99.2 
S1 10.0 10.1 100.9 
S2 20.0 20.6 103.2 
S3 30.0 30.7 102.4 
S4 40.0 39.2 98.0 






Figure 7: Expected vs. experimental Th-232 mass deposition onto filter paper 
 There were a few issues with the process of this method, however. For each sample, 12 
µL drops were deposited onto the filter paper and allowed to dry under a heat lamp. Drying took 
anywhere from 1 hour for the 5 mg sample to ~5 hours for the 50 mg sample due to the relatively 
large number of pipette transfers of solution needed to accumulate that amount of mass onto the 
filter paper. For the higher mass samples, we had to take great care not to supersaturate the filter 
paper, which would result in mass losses to the petri dish holder.  
Furthermore, we had to be careful not to rush the drying process by heating the sample 
too quickly. This resulted in minor effects where the samples bubbled slightly due to the outer 
layer drying much quicker than the inside, trapping air that eventually found a way to escape. A 
major effect occurred once with our first 50 mg trial sample and resulted in the sample dissolving 
the filter paper that it was adhering to (Figure 8.) We realized that this occurred when too much 
heat was added to the system while drying. Because we used 0.1M HNO3, the solution was 




























mostly water; however, as the solution evaporated, the acid slowly concentrated with the most 
concentrated acid produced right before it was fully dried. We believe the combined 
concentrated acid and heat of the heat lamp was responsible for dissolving the filter paper, a 
major concern for precise thorium target preparation.  
 
Figure 8: Dissolved filter paper due to rapid heating and concentration of nitric acid 
5.3. 232Th deposition on aluminum foil 
 We also decided to test depositing our thorium stock solution onto aluminum foils instead 
of filter paper. We stamped out 20 mm diameter circular samples and used a stencil and sharpie 
to outline a 15 mm diameter circle in the center to ensure all of the solution remains on the 
Because the aluminum is not porous like the filter paper, we were able to deposit larger 
quantities of the solution onto the foil, thus, reducing the total time required for the target 
material to deposit and dry onto the aluminum. 5mg, 10mg, 20mg, 30mg, 40mg, and 50mg 
samples of thorium stock solution were prepared, sealed, and quantified via gamma-ray 
spectroscopy. This allowed us to test more samples and ensure the samples were fully dried 




trend is the same as for the filter paper sample results, we calculated a much higher general 
percent yield for the foil targets. We believe that this occurred due to accidental slow 
evaporation of the stock solution during deposition. Throughout the deposition procedure, the 
stock solution lid was removed and left open while we deposited the solution onto the substrate. 
Over time, we believe that solution slowly evaporated since it was located near the heat source 
for sample drying, thus concentrating the stock solution the more we used it.   
Table 12: Deposition results for thorium stock solution onto aluminum foils 







S0.5A 5.0 5.8 115.4 
S1A 10.0 10.3 103.0 
S2A 20.0 22.2 110.8 
S3A 30.0 33.7 112.4 
S4A 40.0 43.6 109.0 
S5A 50.0 56.9 113.8 
 
 
Figure 9: Expected vs. experimental Th-232 mass deposition onto aluminum foils 





















These samples were also analyzed for their radioactivity uniformity via a phosphor-
imaging technique Figures 10-15. The images were processed and overlaid with a 1mm x 1mm 
grid size for visual scale and to ensure the samples remain within the 1.0 – 1.5 cm diameter 
target size objective. Red on the images represents the areas with the highest radioactivity 
distribution and blue represents the areas with the lowest.  
   
Figure 10: 5 mg Th-232 nitrate deposition results. On the left is a photo of the sample immediately after 
drying down. The center image is a close-up of the radioactivity distribution of sample taken through the 
OptiQuant software. The image on the right shows a 1 mm x 1 mm grid overlaid on the phosphor image 
for size. This sample is approximately 8 mm in diameter 
  
  
Figure 11: 10 mg Th-232 nitrate deposition results. The left image is a close-up of the radioactivity 
distribution of sample taken through the OptiQuant software. The image on the right shows a 1 mm x 1 






Figure 12: 20 mg Th-232 nitrate deposition results. The left image is a close-up of the radioactivity 
distribution of sample taken through the OptiQuant software. The image on the right shows a 1 mm x 1 
mm grid overlaid on the phosphor image for scale. This sample is approximately 9 mm in diameter 
 
Figure 13: 30 mg Th-232 nitrate deposition results. The left image is a close-up of the radioactivity 
distribution of sample taken through the OptiQuant software. The image on the right shows a 1 mm x 1 
mm grid overlaid on the phosphor image for scale. This sample is approximately 10 mm in diameter 
 
Figure 14: 40 mg Th-232 nitrate deposition results. The left image is a close-up of the radioactivity 
distribution of sample taken through the OptiQuant software. The image on the right shows a 1 mm x 1 





Figure 15: 50 mg Th-232 nitrate deposition results. The left image is a close-up of the radioactivity 
distribution of sample taken through the OptiQuant software. The image on the right shows a 1 mm x 1 
mm grid overlaid on the phosphor image for scale. This sample is approximately 14 mm in diameter 
 
With both the filter paper and aluminum samples, we observed an interesting phenomena 
that occurred if the thorium samples were left out in open air overnight or over a weekend. We 
noticed that if the samples were dried or nearly dried and then left opened for several hours, the 
samples appeared to be visibly wet again. We also observed this phenomenon over the course of 
several days to weeks after the samples were double-bagged and sealed with tape. Smaller 
samples (i.e. the 5 and 10 mg samples) showed signs of rehydration sooner than larger samples 
(Figure 16.)  
  
Figure 16: Image of 5mg thorium stock solution dried onto aluminum foil. Image taken immediately after 
drying (left.) Note that thorium nitrate dries as a pure white solid. Four days after the sample was double 




After some additional research, we learned that thorium nitrate is an extremely 
hydroscopic chemical compound, which means that it easily rehydrates and absorbs water from 
the air unless tightly sealed or stored in a dessicator [54]. This is a significant concern regarding 
the stability of a 230Th target that needs to be prepared at Oak Ridge National Laboratory in the 
humid environment of Tennessee, sent to Lawrence Livermore National Laboratory in California 
for fast neutron irradiation, and then sent back to ORNL for processing. Therefore, we chose to 
test the use of Kapton tape on the dried samples as a method of sealing and locking out excess 
moisture from the air to prevent sample rehydration (Figure 17.) 
 
Figure 17: Image of second 5 mg thorium nitrate sample immediately after drying and sealed with 
Kapton tape.  
 
Several more small (5 – 20 mg) samples were created to track the stability of the target 
material over time. Figures 18 – 21 summarize the stability of the 5 mg target material with 
Kapton tape over the course of 19 days. At almost three weeks post deposition, the small 5 mg 
target was still solid and intact, and the phosphor images showed a relatively uniform 





Figure 18: Image of second 5 mg thorium nitrate sample (left) and phosphor image (right) 3 days post 
deposition 
  










Figure 21: Image of second 5 mg thorium nitrate sample (left) and phosphor image (right) 10 days post 
deposition 
When we compare side-by-side images of a 5 mg sample with and without Kapton tape 
sealing the material, the results are obvious (Figure 22.) After only 4 days, the sample without 
Kapton tape completely re-liquified after drying although it was contained in two plastic bags. 
The sample with Kapton tape, however, although visibly moist on the inside, was still relatively 
solid and intact 19 days after deposition. This shows that the Kapton tape is extremely effective 
at locking out moisture and increasing the stability of the target necessary for a successful 
experiment and analysis.  
  
Figure 22: Image of first 5 mg thorium nitrate sample 4 days after deposition (left.) The sample was 
completely re-liquified by this point. Image of second 5 mg thorium nitrate with Kapton tape sample 19 




From these experimental results, we determined that an ~25-30 mg thorium nitrate 
sample on high purity aluminum foil sealed with a layer of Kapton tape would be sufficient in 
size and stability for fast neutron irradiation experiments.   
5.4. 232Th deposition into school glue matrix 
 We also chose to test another innovative method of producing a uniform thorium nitrate 
target by mixing it into a school glue matrix and allowing to dry as a thin film (Figure 23.) The 
results of the initial test showed that there were small air bubbles dried into the glue matrix, 
which reduced its unformity. We also shared concerns that the polymer of the glue would 
potentially break down during fast neutron irradiation, and irradiating this glue has never been 
tested before. Furthermore, the preparation of this irradiation target was more complicated that 
the previous two methods investigated. Therefore, the testing of this method was not pursued 
further than this preliminary assessment.   
 
Figure 23: Thorium nitrate dried into a school glue matrix. Small air bubbles were present despite 










Targeted alpha therapy (TAT) is a promising technique for treating metastatic cancer. 
The procedure involves delivering a radionuclide to the cancerous cells within the body, where it 
decays by releasing 5 – 8 MeV alpha particles with high linear energy transfer and relatively low 
toxicity to the rest of the body. 225Ac is an ideal nuclide for TAT for its short half-life and four 
alpha-emitting decay daughters; however, there is currently not enough of the radionuclide to 
meet expected demand. Therefore, the goal of our research was to perform two unique 
experiments associated with the production of the parent isotope, 229Th.  
For this work, we evaluated the effective neutron fission cross section of 229Th to be 8.36 
± 0.37 barns through the thermal neutron irradiation of the radioisotope in the High Flux Isotope 
Reactor (HFIR) at ORNL. This value is much lower than currently reported value of 30.8 ± 1.5 
barns, which would allow for a higher production rate of the medical isotope parent; however, 
more experiments are required to confirm this value. We plan to repeat this experiment by 
irradiating smaller samples for a shorter duration. We will further characterize the target material 
by mass spectroscopy analysis and test methods for fission product recovery by depositing the 
229Th solution onto an aluminum target instead of into a glass ampule.  
 We also tested three methods for preparing a 230Th target for fast neutron irradiation in a 
particle accelerator: deposition of thorium nitrate onto filter paper, onto aluminum foil, and into a 




230Th(NO3)4 onto a high-purity aluminum substrate and sealing the material with Kapton tape to 
prevent rehydration is the best way to produce this target. Staff and other student researchers at 
ORNL are in the process of preparing the enriched 230Th target and plan to send it to LBNL for 
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